Media Pack
News

Current Edition

JCS Volume 15 Issue 2
 
Regional News

Amid Aduhelm’s rocky launch, Biogen eyes large-scale layoffs

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer's disease drug Aduhelm has proven more of a headache than a blessing for d...
13 December 2021 Regional News Aduhelm (aducanumab) | Alzheimer's
Continue Reading →
Regional News

ARIA side effects surface in 40% of patients on Biogen’s Alzheimer’s drug Aduhelm

Biogen's Alzheimer's disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the drug won ...
24 November 2021 Regional News Aduhelm (aducanumab) | Alzheimer's
Continue Reading →
Regional News

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer's disease drug Aduhelm, the company is also feeling the heat from a ...
16 September 2021 Regional News Aduhelm | Alzheimer's
Continue Reading →
Europe

Topeka man involved in Alzheimer’s clinical trial

About 5 years ago, Topeka man, Allen Davis started to experience symptoms of Alzheimer's Disease and Dementia. Now he's focused on one thing. "Hopefully it's not get...
31 July 2018 Europe Alzheimer's | clinical
Continue Reading →
Europe

High Point Company’s Alzheimer’s Drug Trial Fails

The drug was in development for close to two decades. Experts say that without new drugs, Alzheimer’s efforts will need to focus on prevention. High Point-based vTv T...
11 April 2018 Europe | Uncategorized Alzheimer's | company
Continue Reading →
 
 
 
jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte